Mr. T.J. Crawford reports

BAUSCH + LOMB ANNOUNCES DISCLOSURE OF HISTORICAL AND PRO FORMA FINANCIAL INFORMATION WITH RESPECT TO ACQUISITION OF XIIDRA

Bausch + Lomb Corp. has disclosed certain historical and pro forma financial information with respect to its proposed acquisition of Xiidra (lifitegrast ophthalmic solution) 5 per cent and certain other ophthalmology assets on a current report on Form 8-K and on its SEDAR+ profile. In connection with the acquisition, as previously disclosed, Bausch + Lomb anticipates incurring indebtedness (expected to be composed principally of an incremental term loan and the issuance of senior secured notes), which is discussed in further detail in its current report on Form 8-K.

About Bausch + Lomb Corp.

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products, and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing, and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ont., with corporate offices in Bridgewater, N.J.

We seek Safe Harbor.